Positive Results of Cryolife's Synergraft(R) Arteriovenous Access Device In Dialysis Patients Presented At A European Medical Co
September 16 2004 - 3:31PM
PR Newswire (US)
Positive Results of Cryolife's Synergraft(R) Arteriovenous Access
Device In Dialysis Patients Presented At A European Medical
Congress 83% Secondary Patency at One Year ATLANTA, Sept. 16
/PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE:CRY), a biomaterials
and biosurgical device company, announced today that Mr. Chris
Darby, of the Oxford Transplant Center at Churchill Hospital in
Oxford, UK, presented positive results of the SynerGraft(R)
arteriovenous (AV) access device, which showed secondary patency of
83% and freedom of infection of 94% at one year in patients
undergoing dialysis. These results were presented today at the
Advances in Tissue Engineering and Biology of Heart Valves
Conference in Florence, Italy. CryoLife's SynerGraft AV access
device, made of a bovine ureter, is only approved in Europe for
dialysis patients. Mr. Darby implanted the SynerGraft AV access
device in 17 high-risk patients who failed previous access methods
for dialysis. "The SynerGraft AV access device may offer advantages
over synthetic grafts, which are prone to early failure due to
infection," said Mr. Darby. "Based on the data from these 17
patients, this device has the ability to repair damage from
needling and remove infection from needle holes. It provides an
alternative when an autologous vein is not available." The
SynerGraft AV access device is not available in the U.S. This
SynerGraft device utilizes the Company's antigen reduction
technology (ART). This patented process removes antigens from the
tissues, which appears to allow the patient to receive the implant
without using immunosuppressant therapy. Statements made in this
press release that look forward in time or that express
management's beliefs, expectations or hopes are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These future events may not occur as and when
expected, if at all, and, together with the Company's business, are
subject to various risks and uncertainties. These risks and
uncertainties include that results obtained from other implants of
the SynerGraft arteriovenous access device may not prove as
positive as those reported, that the SynerGraft arteriovenous
access device may not offer advantages over synthetic grafts, may
not repair damage from needling, or remove infection from needle
holes, and that patients receiving implants processed using the
company's antigen reduction technology may require
immunosuppressant therapy despite current indications to the
contrary. The risks and uncertainties also include the risk that
the Company's 2004 revenues and expenses may not meet its
expectations, the possibility that the FDA could impose additional
restrictions on the Company's operations, require a recall, or
prevent the Company from processing and distributing tissues or
manufacturing and distributing other products, that FDA regulation
of the Company's CryoValve SG and CryoVein SG may require
significant time and expense, that the Company may not have
sufficient borrowing or other capital availability to fund its
business, that pending litigation cannot be settled on terms
acceptable to the Company, that the Company may not have sufficient
resources to pay punitive damages (which are not covered by
insurance) or other liabilities in excess of available insurance,
the possibility of severe decreases in the Company's revenues and
working capital, that to the extent the Company does not have
sufficient resources to pay the claims against it, it may be forced
to cease operations or seek protection under applicable bankruptcy
laws, changes in laws and regulations applicable to CryoLife and
other risk factors detailed in CryoLife's Securities and Exchange
Commission filings, including CryoLife's Form 10-K filing for the
year ended December 31, 2003, and the Company's other SEC filings.
The Company does not undertake to update its forward-looking
statements. For additional information about the company, visit
CryoLife's Web site: http://www.cryolife.com/ Contact: Joseph T.
Schepers Vice President, Corporate Communications (770) 419-3355
DATASOURCE: CryoLife, Inc. CONTACT: Joseph T. Schepers, Vice
President, Corporate Communications of CryoLife, Inc.,
+1-770-419-3355 Web site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024